2,2-difluoropropionamide derivatives of bardoxolone methyl, polymorphic forms and methods of use thereof
The present invention relates generally to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide, polymorphic forms thereof, methods for preparation and use thereof, pharmaceutical compositions thereof, and kits and articles of manufacture thereof.
1. A polymorphic form of a compound of the formula:
wherein the polymorphic form has an X-ray powder diffraction pattern (CuKα) comprising a halo peak at about 14° 2θ, further having a T g of about 153° C.
2. A polymorphic form of a compound of the formula:
wherein the polymorphic form is a solvate having an X-ray powder diffraction pattern (CuKα) comprising peaks at about 5.6, 10.6, and 14.6° 2θ.
3. A polymorphic form of a compound of the formula:
wherein the polymorphic form is a solvate having an X-ray powder diffraction pattern (CuKα) comprising peaks at about 7.0, 7.8, 11.9, 13.9 (double peak), and 16.0° 2θ.
4. A polymorphic form of a compound of the formula:
wherein the polymorphic form is an acetonitrile hemisolvate having an X-ray powder diffraction pattern (CuKα) comprising peaks at about 7.5, 15.6, and 16.6° 2θ.
5. A polymorphic form of a compound of the formula:
wherein the polymorphic form is a solvate having an X-ray powder diffraction pattern (CuKα) comprising peaks at about 9.3, 9.5, 10.5, 13.6, and 15.6° 2θ.
6. A pharmaceutical composition comprising:
an active ingredient consisting of a polymorphic form of claim 1 , and
a pharmaceutically acceptable carrier.
7. The pharmaceutical composition according to claim 6 , wherein the pharmaceutical composition is formulated for administration: orally, intraadiposally, intraarterially, intraarticularly, intracranially, intradermally, intralesionally, intramuscularly, intranasally, intraocularly, intrapericardially, intraperitoneally, intrapleurally, intraprostatically, intrarectally, intrathecally, intratracheally, intratumorally, intraumbilically, intravaginally, intravenously, intravesicularlly, intravitreally, liposomally, locally, mucosally, parenterally, rectally, subconjunctival, subcutaneously, sublingually, topically, transbuccally, transdermally, vaginally, in crèmes, in lipid compositions, via a catheter, via a lavage, via continuous infusion, via infusion, via inhalation, via injection, via local delivery, or via localized perfusion.
8. The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition is formulated for oral, intraarterial, intravenous or topical administration.
9. The pharmaceutical composition of claim 7 , wherein the pharmaceutical composition is formulated for oral administration.
10. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is formulated as a hard or soft capsule, a tablet, a syrup, a suspension, an emulsion, a solution, a solid dispersion, a wafer, or an elixir.
11. The pharmaceutical composition of claim 6 , wherein the pharmaceutical composition is formulated for topical administration.
12. The pharmaceutical composition of claim 11 , wherein pharmaceutical composition is formulated as a lotion, a cream, a gel, an oil, an ointment, a salve, an emulsion, a solution, or a suspension.
13. The pharmaceutical composition of claim 6 , wherein the amount of the active ingredient is from about 0.01% to about 5% by weight.
14. A method of treating a condition associated with inflammation or oxidative stress, selected from the group consisting of prostate cancer, dermatitis, sepsis, pulmonary inflammation, pulmonary fibrosis, COPD, asthma, mucositis, and ocular inflammation, in a patient in need thereof, comprising administering to the patient a therapeutically effective amount of the polymorphic form of claim 1 .
15. The method of claim 14 , wherein the condition is dermatitis.